Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity
Status:
Completed
Trial end date:
2021-12-02
Target enrollment:
Participant gender:
Summary
Anthracyclines are one of the most well-known and effective drugs used to treat
malignancies.The most important limiting factor in the use of this drug is its cardiac
toxicity which includes cardiomyopathy and congestive heart failure. Bisoprlol is a
β1-specific β-blocker that can reduce cardiac overload and also have anti-inflammatory
antioxidant effects and can reduce reactive oxygen metabolites so it can be used as a
cardioprotective agent in patients with a high risk of heart failure. To the best of our
knowledge, no study has been performed to evaluate the prophylactic effect of bisoprolol
solely in patients under chemotherapy with anthracyclines. This study is aimed to evaluate
the cardioprotective role of bisoprolol in patients with non-metastatic breast cancer
receiving doxorubicin, by measuring global longitudinal strain before and after treatment.